<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Crit Care</journal-id>
      <journal-title-group>
        <journal-title>Critical Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1364-8535</issn>
      <issn pub-type="epub">1466-609X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21418550</article-id>
      <article-id pub-id-type="pmc">3219314</article-id>
      <article-id pub-id-type="publisher-id">cc10041</article-id>
      <article-id pub-id-type="doi">10.1186/cc10041</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Recombinant factor VIIa and factor VIII treatment for acquired factor VIII deficiency: a case of repeated thrombotic endotracheal occlusion in a mechanically ventilated patient</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Lauer</surname>
            <given-names>Stefan</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>stlauer@gmx.net</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Westphal</surname>
            <given-names>Martin</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>Martin.Westphal@gmx.net</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Fischer</surname>
            <given-names>Lars G</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>fischla@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Mei&#xDF;ner</surname>
            <given-names>Andreas</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>a.meissner@uni-muenster.de</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Van Aken</surname>
            <given-names>Hugo</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>hva@anit.uni-muenster.de</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Freise</surname>
            <given-names>Hendrik</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>freiseh@uni-muenster.de</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Anesthesiology and Intensive Care Medicine, University Hospital Muenster, Albert-Schweitzer-Str. 33, 48149 Muenster, Germany</aff>
      <aff id="I2"><label>2</label>Fresenius Kabi AG, Else-Kr&#xF6;ner-Strasse 1, 61352 Bad Homburg, Germany</aff>
      <pub-date pub-type="ppub">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>3</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the epub date.-->
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>3</month>
        <year>2012</year>
      </pub-date>
      <volume>15</volume>
      <issue>2</issue>
      <fpage>407</fpage>
      <lpage>407</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9;2011 BioMed Central Ltd</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>BioMed Central Ltd</copyright-holder>
      </permissions>
      <self-uri xlink:href="http://ccforum.com/content/15/2/407"/>
    </article-meta>
  </front>
  <body>
    <sec>
      <title/>
      <p>Acquired hemophilia A is caused by autoantibodies to coagulation factor VIII (FVIII). Preoperative diagnosis is impaired by the lack of a personal or family history of bleeding episodes. Therefore, surgical procedures can lead to life-threatening hemorrhage [<xref ref-type="bibr" rid="B1">1</xref>].</p>
      <p>We present a case of a 72-year-old woman who had no history of coagulopathy and who was undergoing hysteroscopy and abrasion in a district hospital. Persistent vaginal bleeding began immediately after surgery, resulting in vaginal hysterectomy on postoperative day (POD) 7 and multiple re-laparotomies with intermittent abdominal packing between PODs 8 and 37. Acquired FVIII deficiency was suspected on POD 30, but a disseminated intravascular coagulation and treatment with various pro-coagulants made the definitive diagnosis difficult. Bolus applications of recombinant factor VIIa (rFVIIa) and von Willebrandt factor-FVIII complex between PODs 33 and 38 plus prednisolone pulse therapy remained ineffective. Acquired FVIII deficiency was finally diagnosed upon admission of the intubated and ventilated patient to the intensive care unit of a university hospital on POD 40. Further FVIII was administered because of persistent surgical bleeding. Following massive abdominal bleeding on POD 44, the patient received FVIII for the next 24 hours and rFVIIa until POD 49. On POD 47, the abdominal bleeding ceased.</p>
      <p>Three life-threatening airway complications occurred under rFVIIa and FVIII therapy. On POD 40, the endotracheal tube (ETT) was completely obstructed by blood clots. On POD 46, pulmonary gas exchange rapidly deteriorated because of a huge thrombus in the left main bronchus (2 &#xD7; 5 cm). On POD 49, a large endobronchial thrombus (2 &#xD7; 7 cm), which was attached to the tip of the ETT, was fortunately extracted during the emergency removal of the ETT (Figure <xref ref-type="fig" rid="F1">1a</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>A bronchial thrombus critically obstructed the airways in a long-term ventilated patient under recombinant factor VIIa and factor VIII therapy</bold>. <bold>(a) </bold>The thrombus (arrow) was still attached to the tip of the removed endotracheal tube. <bold>(b) </bold>The detached thrombus (arrow) was approximately 20 &#xD7; 70 mm. With its solid consistency, it occluded the tip of the endotracheal tube and the airways like a cork.</p>
        </caption>
        <graphic xlink:href="cc10041-1"/>
      </fig>
      <p>Each time, bronchoscopy showed only moderate diffuse bleeding from minor mucosal erosions. After the critical incident on POD 49, the patient was weaned from the respirator and eventually fully recovered.</p>
      <p>Intravascular thromboembolic events under treatment with rFVIIa and FVIII present a well-known complication [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Life-threatening thrombotic airway obstructions in a mechanically ventilated patient, however, are a rare complication. The fact that activated partial thromboplastin times (aPTTs) were spontaneously prolonged (53 to 66 seconds) and active bleeding was present during these events highlights the unpredictable local imbalance of pro- and anticoagulant effects during such a treatment. In conclusion, intensive care clinicians should be aware that minor lacerations of the bronchial mucosa in mechanically ventilated patients could lead to blood clots and critical airway obstruction under the treatment with rFVIIa and FVIII.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>ETT: endotracheal tube; FVIII: factor VIII; POD: postoperative day; rFVIIa: recombinant factor VIIa.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>Written consent for publication was obtained from the patient.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Brack</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Vogeler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hilpert</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Berger</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Buhr</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Koscielny</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Acquired factor VIII inhibitor</article-title>
          <source>Anesthesiology</source>
          <year>2009</year>
          <volume>111</volume>
          <fpage>1151</fpage>
          <lpage>1154</lpage>
          <pub-id pub-id-type="doi">10.1097/ALN.0b013e3181b64ad2</pub-id>
          <pub-id pub-id-type="pmid">19809294</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Barletta</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Cooper</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Ohlinger</surname>
            <given-names>MJ</given-names>
          </name>
          <article-title>Adverse drug events associated with disorders of coagulation</article-title>
          <source>Crit Care Med</source>
          <year>2010</year>
          <volume>38</volume>
          <fpage>S198</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="doi">10.1097/CCM.0b013e3181de11f9</pub-id>
          <pub-id pub-id-type="pmid">20502174</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Vincent</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Rossaint</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Riou</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Ozier</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zideman</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Spahn</surname>
            <given-names>DR</given-names>
          </name>
          <article-title>Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective</article-title>
          <source>Crit Care</source>
          <year>2006</year>
          <volume>10</volume>
          <fpage>R120</fpage>
          <pub-id pub-id-type="pmid">16919168</pub-id>
          <pub-id pub-id-type="doi">10.1186/cc5026</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
